Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential and standard of care of Janssen's BALVERSA (erdafitinib) for the treatment of urothelial carcinoma based on the data that was recently presented at ASCO 2023

Ticker(s): JNJ

Who's the expert?

Institution: One Urology

Urologist at One Urology in California.
Currently manages 125-200 patients with bladder cancer.
Clinical interests: General urologic conditions including urologic cancer, stone disease, incontinence, erectiledysfunction, men’s health, and infertility.

Interview Goal

This interview will focus on the recent data presented at ASCO 2023 regarding the THOR Phase III trial and the NORSE Phase Ib-II trial which evaluated the safety and clinical activity of Janssen's BALVERSA (erdafitinib) in patients with metastatic or locally advanced urothelial cancer.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.